High Pregnancy, Cord Blood, and Infant Vitamin D Concentrations May Predict Slower Infant Growth by Hauta-alus, Helena H. et al.
C L I N I C A L R E S E A R C H A R T I C L E
High Pregnancy, Cord Blood, and Infant Vitamin D
Concentrations May Predict Slower Infant Growth
Helena H. Hauta-alus,1 Eero Kajantie,1,2,3,4 Elisa M. Holmlund-Suila,1
Jenni Rosendahl,1 Saara M. Valkama,1 Maria Enlund-Cerullo,1 Otto M. Helve,1
Timo K. Hytinantti,1 Heli Viljakainen,5,6 Sture Andersson,1 and Outi Mäkitie1,7,8
1Children’s Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital,
Helsinki 00020, Finland; 2National Institute for Health and Welfare, Helsinki 00271, Finland; 3PEDEGO
Research Unit, Me Oulu, Oulu University Hospital and University of Oulu, Oulu 90014, Finland; 4Department
of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim 7491,
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Context: The relationship of maternal and infant 25-hydroxyvitamin D concentration [25(OH)D]
with infant growth is unclear.
Objective:Our objective was to explore whether 25(OH)D in pregnancy, umbilical cord blood (UCB),
or in infancy was associated with infant growth.
Design: This study involved 798 healthy infants and their mothers in Finland. We assessed 25(OH)D
during pregnancy, from UCB at birth, and from the infant at the age of 12 months.
Main Outcome Measures: Infant length, weight, length-adjusted weight, and head circumference
at 6 and 12 months and midupper-arm circumference at 12 months.
Results: Of the mothers and infants, 96% and 99% were vitamin D sufficient [25(OH)D $50 nmol/L],
respectively. Mothers with pregnancy 25(OH)D.125 nmol/L had the shortest, lightest (in weight), and
thinnest (in length-adjusted weight) infants at 6 months (P for all , 0.05). For each 10 nmol/L higher
UCB 25(OH)D, the infants were 0.03 SD score (SDS) shorter at 6 months (95% CI 20.05 to 20.01),
adjusted for birth size, infant 25(OH)D, and parental height. Higher UCB 25(OH)D associated with
smaller head circumference at 6 and 12 months (P for all ,0.05) but attenuated after adjustments.
Mothers with pregnancy 25(OH)D .125 nmol/L had the thinnest infants at 12 months (P = 0.021). For
each 10 nmol/L higher infant 25(OH)D, the infants were 0.03 SDS lighter (20.05 to20.01) and 0.03 SDS
thinner (20.05 to 0.00) at 12 months.
Conclusions:Our results suggest that highpregnancy, cordblood, and infant vitaminD concentrationmay
have disadvantageous effects on infant growth. (J Clin Endocrinol Metab 104: 397–407, 2019)
Several studies have associated poor maternal vitaminD status with fetal growth restriction (1–3). The few
studies examining whether and how maternal or infant
vitamin D status affect postnatal growth in the infant
show inconsistent results. Many observational studies
have found no association between maternal vitamin D
status and linear growth in infants or older children
(4–8). However, a randomized trial of maternal vitamin
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D supplementation in Bangladesh, with mean baseline
25-hydroxyvitaminD [25(OH)D] concentrationof 42nmol/L,
resulted in greater offspring length at 12 months of age (9).
In children, severe vitamin D deficiency increases the
risk of rickets, which can lead to growth impairment (10).
Indeed, among low-birth-weight infants in India, among
whom vitamin D deficiency was common, a weekly vi-
taminD supplementation of 35mg improved infant linear
growth compared with placebo (11). However, a Ca-
nadian vitamin D intervention study (with vitamin D
doses of 10, 20, 30, and 40 mg) in 132 healthy infants
showed no difference between the groups in growth at
11 months despite different 25(OH)D, although this
study may have been underpowered (12).
Previous studies have largely lacked subjects with high
25(OH)D concentrations and have focused on the effects
of very low vitamin D status or vitamin D supplemen-
tation in vitamin D–deficient children on infant growth.
In addition, studies have rarely included data for both
maternal and infant 25(OH)D concentrations. In Fin-
land, vitamin D supplementation is recommended for
pregnant women and all children, and vitamin D food
fortification is used in liquid dairy products and fat
spreads (13). Our objective was to explore whether
25(OH)D in pregnancy, umbilical cord blood (UCB), or
infancy at 12 months of age are associated with growth
parameters in 6-month-old and 12-month-old infants.
This study was part of the Vitamin D Intervention in
Infants (VIDI) study, a randomized trial on vitamin D
supplementation with the standard (10 mg) or a higher
dose (30 mg) of vitamin D3 in infants.
Materials and Methods
Subjects
At Kätilöopisto Maternity Hospital (Helsinki, Finland), 987
families were recruited into the VIDI study between January
2013 and June 2014, during the mother’s hospital stay after
delivery. Written informed consent was obtained from the
parents at recruitment. This study was conducted according to
the guidelines laid down in the Declaration of Helsinki. Ethical
approval was obtained from the Research Ethics Committee of
the Hospital District of Helsinki and Uusimaa (107/13/03/03/
2012). The project protocol is registered at clinicaltrials.gov
(NCT01723852). According to the inclusion criteria, the mothers
were ofNorthern European originwithout regularmedication and
with singleton pregnancy. Exclusion criteria for the newborns
were: nasal continuous positive airway pressure treatment or need
for nasogastric tube .1 day, intravenous glucose infusion, sei-
zures, and duration of phototherapy .3 days. The infants were
born between 37 and 42 weeks of gestation with birth weights
appropriate for gestational age [SD score (SDS) between 22.0
and 2.0].
Infants were randomized to receive daily vitamin D3 sup-
plementation with either 10 mg or 30 mg from age 2 weeks to
24 months. We have previously reported that at the age of
12 months, in addition to the supplemental dose, nonbreastfed
infants (n = 476) received 0.6 to 28.3 and breastfed infants (n =
263) 0 to 30.7 mg of vitamin D daily from food (14). The VIDI
study included three study visits at the ages of 6, 12, and 24months
and multiple retrospectively and prospectively collected question-
naires. A detailed description of the recruitment and study protocol
has been reported previously (15).
Of the recruited 987 families, 12 did not meet the inclusion
criteria and were excluded, leaving 975 study participants. In
addition, 87 infants withdrew prior to 6 months, and a further
15 withdrew prior to 12 months, leaving 873 infants with body
size measurements. Of these infants, 74 did not have 25(OH)D
measurements, and 1 infant was excluded after a diagnosis of
Rieger syndrome. The final study cohort for this study thus
comprised 798 infants (Supplemental Figure 1). Of the infants,
51% (409 out of 798) were girls. Number of subjects varies in
different analyses due to partial missing data and is reported in
the tables. As data on the infants’ vitamin D supplemental dose
were unavailable for this study, we adjusted the analyses for
Infant 25(OH)D at 12 months as a marker of total vitamin D
intake including supplements.
Biochemical analyses
25(OH)Dmeasurements were obtained at three time points for
each subject. Pregnancy serum samples were collected at prenatal
clinics on average (SD) at gestational week 11 (2) between June
2012 and February 2014 as part of themothers’ normal follow-up
[hereafter referred to as Pregnancy 25(OH)D]. Pregnancy samples
were stored in the Finnish Maternity Cohort serum bank orga-
nized by the National Institute for Health and Welfare. UCB for
25(OH)D measurement was obtained at birth (gestational weeks
37 to 42) between January 2013 and June 2014 [hereafter referred
to as UCB 25(OH)D]. At the 12-month follow-up visit, infant
serum samples were obtained between December 2013 and June
2015 and analyzed for 25(OH)D [hereafter referred to as Infant
25(OH)D] and intact PTH.
Pregnancy serum and UCB plasma 25(OH)D were ana-
lyzed simultaneously, and Infant serum 25(OH)D and PTH in a
separate series using the IDS-iSYS fully automated immunoassay
system with chemiluminescence detection (Immunodiagnostic
Systems Ltd., Bolton, United Kingdom) with intra-assay varia-
tion ,7% for Pregnancy 25(OH)D, Infant 25(OH)D, and PTH
and ,13% for UCB 25(OH)D. Detailed information on UCB
plasma 25(OH)D (16) and Pregnancy 25(OH)D analysis (17) has
been previously reported. The quality and accuracy of the
25(OH)D analyses are validated on an ongoing basis by par-
ticipation in the vitamin D External Quality Assessment Scheme
(Charing Cross Hospital, London, United Kingdom). The
method showed a#8%positive bias againstNational Institute of
Standards and Technology Reference Measurement Procedure.
We defined vitamin D deficiency as 25(OH)D ,50 nmol/L
(18) and vitamin D sufficiency as 25(OH)D $50 nmol/L (19).
Furthermore, we divided subjects into groups based on 25(OH)
D concentrations using an additional cutoff values of 75 nmol/L,
which has been considered a lower threshold value for bone
health (18), and 125 nmol/L, above which values have been
related to health risks (19).
Parental data
Parental data were obtained from a self-administered baseline
questionnaire, filled out after delivery, and frommedical records.
Parental heights (centimeters) and weights (kilograms) before
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pregnancy and parity were collected primarily from the prenatal
maternity card or from our baseline questionnaire. Parental
heights were standardized into sex-specific z scores. Prepreg-
nancy body mass index (BMI) was calculated (kilograms per
meters squared). Duration of gestation was determined by first-
trimester ultrasound examination.
Parental education level was categorized into lower and higher
education (lower is lower or upper secondary or postsecondary
nontertiary education or less than a bachelor degree, and higher is
first or second stage of tertiary education or at least a bachelor
degree), according to the highest received degree of the parents.
Parental smoking status was assessed before pregnancy and at
infant age of 24 months and applied as a merged previous and
current smoking status. Family income level was inquired with a
questionnaire completed at infant age of 24 months.
Infant data
Birth size was measured by midwives according to standard
procedure, and we collected data from birth records. Infant
weight (kilograms), length (centimeters), and head circumference
(centimeters) were measured at the 6-month and 12-month
follow-up visits by a pediatrician or a research nurse. In addition,
at the 12-month follow-up visit, midupper-arm circumference
(MUAC; millimeters) was measured. Length was measured
with a tabletop meter in a supine position and weight with an
electronic scale (Seca GmbH, Hamburg, Germany). Weight,
length, length-adjusted weight, and head circumference were
expressed as SDS using age-specific and sex-specific Finnish
references (20).Weight, length, length-adjusted weight, and head
circumference were considered normal when between 22.0 and
2.0 SDS. MUAC was standardized into sex-specific z score
within the current study population, as no Finnish normative
data exist. Duration of breastfeeding was determined based on
repeated questionnaires in prospectively collected study diaries.
Statistical analysis
The normality of the variables was visually inspected. Infant
and family characteristics were reported as means, SDs, and
percentages. Nonparametric methods were used where ap-
propriate. Independent variables were Pregnancy, UCB, and
Infant 25(OH)D concentrations, and outcome variables were
infant size at 6 and 12 months of age (9 outcomes altogether).
Covariates were chosen based on their statistically significant
association with several outcome measures. To assess the in-
dependent effect of Pregnancy and UCB 25(OH)D on growth,
we adjusted the analyses for Infant 25(OH)D concentration at
12 months of age as a marker of the postnatal supplemental
vitamin D intake. Missing values of covariates were multiple
imputed (five imputations). In tables with infant and family
characteristics (Tables 1 and 2), all values are nonimputed.
A change in infant growth (length, weight, length-adjusted
weight, and head circumference) between birth and 6 and
12 months of age was calculated by saving the residuals from
linear regression models of body size SDS at each successive age
vs the corresponding body size SDS at all earlier ages (21). These
residuals were referred to as “conditional growth.” The cor-
responding birth size and size at 6 months of age were adjusted
for in the analyses of conditional growth. Using conditional
growth indicators as outcomes enabled us to explore whether
25(OH)D had an effect on the growth rate among different
growth periods.
Univariate and multivariate linear regression analysis was
used to explore associations between 25(OH)D and infant
growth and conditional growth. We used three regression
models. In the tables, we show an unadjusted model 1 and
model 2, which is adjusted for variables that are essential to
describe the association between 25(OH)D concentration and
early growth independent of genetic determinants of growth.
These variables included SDS of the corresponding birth size,
maternal and paternal height z scores, and Infant 25(OH)D
[except in analyses in which Infant 25(OH)D served as the
independent variable]. In the text, we report model 3, which is
further adjusted for potential confounders that can be expected
to have a causal effect on the predictor and outcome: maternal
and paternal prepregnancy BMI, parental smoking status,
parental education level, family income level, and duration of
breastfeeding. The analyses on conditional growth were con-
ducted in a similar manner. Quadratic associations were ex-
plored with linear regression by adding the corresponding
25(OH)D squared in the growth models 1 and 2. In models of
linear regression, residuals were plotted to assess their normal
distribution and evaluate heteroscedasticity.
Infant size was investigated in categories of 25(OH)D with
analysis of covariance adjusted for corresponding birth size
SDS, maternal and paternal height z scores, and Infant
25(OH)D [except in analyses in which Infant 25(OH)D served
as the independent variable]. Differences in infant size were
compared between categories of 25(OH)D with linear re-
gression using the 25(OH)D category of 50 to 74.9 nmol/L as a
reference group. Statistical significance was determined at P ,
0.05. All statistical analyses were conducted using the IBMSPSS
program for Windows, version 22 (IBM, Chicago, IL).
Results
Infant and family characteristics are presented in Tables 1
and 2. Almost all infants had normal body size (weight
and length between 22.0 and 2.0 SDS) at 6 and
12 months of age. Of the infants, 79% were partially
breastfed at 6 months and 40% at 12 months of age.
Of the mothers, 96% were vitamin D sufficient
[25(OH)D $50 nmol/L], and 99% of the infants were
vitamin D sufficient. Altogether, 2% of Pregnancy,
4% of UCB, and 17% of Infant 25(OH)D values
were.125 nmol/L, ranging up to 189 nmol/L, 284 nmol/L,
and 241 nmol/L, respectively. Correlation coefficient
between Pregnancy and UCB 25(OH)D was r = 0.27
(P , 0.001); between UCB and Infant at 12 months,
25(OH)D was r = 0.15 (P , 0.001); and between
Pregnancy and Infant at 12 months, 25(OH)D was
r = 0.07 (P = 0.081). Infants’ PTH concentration at
12 months declined with increasing Infant 25(OH)D
concentration (Supplemental Table 1).
All linear and quadratic associations between 25(OH)D
concentrations and infant growth are shown in Tables 3
and 4. Conditional growth results are shown in Supple-
mental Tables 2 and 3. We categorized 25(OH)D con-
centrations into four groups:,50nmol/L, 50 to 74.9 nmol/L









elsinki. Social science library user on 23 April 2019
(reference group), 75 to 125 nmol/L, and .125 nmol/L
(Figs. 1 and 2). Infant growth in the lowest and the two
highest 25(OH)D groups was compared with the refer-
ence group of 50 to 74.9 nmol/L. Pregnancy 25(OH)D
predicted length-adjusted weight at 6 and 12 months
(Tables 3 and 4). At 6 months, mothers whose Pregnancy
25(OH)D was .125 nmol/L had the shortest (in length;
mean difference 0.41 SDS; P = 0.048), lightest (in weight;
mean difference 0.63 SDS; P = 0.016), and thinnest (in
length-adjusted weight; mean difference 0.70 SDS; P =
0.013) infants compared with the reference group (Fig. 1).
We found a quadratic association between Pregnancy
25(OH)D and length at 12 months (Table 4). We also ob-
served an inverse association between Pregnancy 25(OH)D
and MUAC (Table 4). The 12-month MUAC was smaller in
the group with Pregnancy 25(OH)D at 75 to 125 nmol/L
(mean difference 0.17 SDS; P = 0.049) compared with the
reference group (Fig. 2). At 12 months of age, infants of
mothers with the highest Pregnancy 25(OH)D were the
thinnest (mean difference 0.60 SDS;P= 0.021) comparedwith
the reference group (Fig. 2).
Infants with higher UCB 25(OH)D were shorter at
6months (Table 3) and had a smaller head circumference at
6 and 12 months, although this attenuated to non-
significance when adjusted (Tables 3 and 4). Furthermore,
infants withUCB25(OH)D.125 nmol/Lwere the shortest
at 6 months compared with the reference group (mean
difference 0.39 SDS; P = 0.011) (Fig. 1). As demonstrated
by conditional lengths, infants with higher UCB 25(OH)D
grew more slowly between birth and 6 months but more
rapidly between 6 and 12 months (Supplemental Tables 2
and 3). Newborns with UCB 25(OH)D ,50 nmol/L were
the thinnest at 6 months (mean difference 0.45 SDS; P =
0.034) compared with the reference group (Fig. 1).
Table 1. Infant Characteristics (n = 798)
At Birth At 6 Mo At 12 Mo
Gestational age, wk 40.2 (1.1) — —
Age, mo — 6.0 (0.2) 12.0 (0.4)
Length, cm 50.4 (1.7) 67.5 (2.2) 75.3 (2.5)
Length, SDS 20.19 (0.88) 20.47 (0.97) 20.54 (1.01)
Weight, kg 3.5 (0.4) 8.0 (0.9) 9.8 (1.1)
Weight, SDS 20.26 (0.79) 0.21 (1.07) 20.24 (1.01)
Length-adjusted weight, SDS 0.07 (0.94) 0.15 (1.11) 0.02 (1.02)
Head circumference, cma 35.2 (1.4) 43.6 (1.2) 46.5 (1.2)
Head circumference, SDSa 20.16 (0.97) 20.30 (0.94) 20.42 (0.94)
MUAC, cmb — — 15.3 (1.2)
Blood 25(OH)D, nmol/L [range]c 82.5 (25.8) [36.7–283.7] — 98.9 (29.0) [23.0–241.0]
Blood 25(OH)D $50 nmol/L, %c 96 — 99
Normal length SDS (22.0 to 2.0), % 98 94 93
Normal weight SDS (22.0 to 2.0), % 100 94 96
Normal length-adjusted weight SDS (22.0 to 2.0),% 96 94 96
Normal head circumference SDS (22.0 to 2.0), %a 95 96 96
Breastfed, %d — 79 40
Sex, female, % 51 51 51
Data are means (SD) unless stated otherwise. Dash indicates no data available.
aAt birth, 2 values are missing; at 6 mo follow-up, 21 values are missing; and at 12 mo follow-up, 5 values are missing.
bTotal of 39 values are missing.
cSamples at birth are from UCB, and 18 values are missing. Samples at 12 mo are from infant serum.
dTotal of 13 values are missing.
Table 2. Family Characteristics
n Mean (SD)
Maternal age, y 798 31.7 (4.3)
Paternal age, y 759 33.6 (5.3)
Maternal height, cm 798 166.4 (6.0)
Paternal height, cm 778 180.3 (6.6)
Maternal prepregnancy BMI 794 23.2 (3.6)
Paternal prepregnancy BMI 771 25.7 (3.4)
Pregnancy 25(OH)D, nmol/L
[range]







Parity, primipara, % 797 63
Maternal smoking, yes, %a 793 16
Paternal smoking1, yes, % 784 26
Parental education, higher, %b 789 81
Family income level 689
,40,000 V/y, % 19
40,000–89,000 V/y, % 60
.90,000 V/y, % 21
Data are means (SD) unless stated otherwise.
aPrevious and current smoking status.
bHigher education reflects at least a bachelor level education.
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Ahigher Infant 25(OH)D at 12months was associated
with smaller length, weight, length-adjusted weight, and
head circumference at 12 months, although the associa-
tions with length and head circumference attenuated with
adjustments (Table 4). Furthermore, infants with 25(OH)
D .125 nmol/L at 12 months had the smallest weight
(mean difference 0.25 SDS; P = 0.022) and length-
adjusted weight (mean difference 0.25 SDS; P = 0.032)
compared with the reference group (Fig. 2).
For the regression analyses assessing the relationship
between 25(OH)D concentrations and growth (Tables 3
and 4), we further adjusted for the following potential
confounding factors: maternal and paternal prepreg-
nancy BMI, parental smoking status, parental education
level, family income level, and duration of breastfeeding)
(data not shown). Results remained similar except for the
association between Pregnancy 25(OH)D and MUAC at
12 months of age, which disappeared.
Discussion
In this study, we demonstrate that high 25(OH)D in the
mother and infant were associated with slower postnatal
growth in a large prospective study of healthy full-term
infants. This study is among the few to explore whether
maternal and infant vitamin D statuses were associated
with growth parameters in 6- and 12-month-old infants.
The study was carried out in a population of northern
latitude but where severe vitamin D deficiency is rare.
Almost all mothers and infants were vitamin D sufficient
[25(OH)D $50 nmol/L]. Our main finding was coun-
terintuitive: high 25(OH)D in pregnancy, UCB, and in-
fancy associated with delayed growth in infants.
The main findings showed that mothers with Preg-
nancy 25(OH)D .125 nmol/L had the shortest (in
length), lightest (in weight), and thinnest (in length-
adjusted weight) infants at 6 months of age. Infants of
these mothers also had the lowest length-adjusted weight
at 12 months of age. Similarly, infants with higher UCB
25(OH)Dwere shorter at 6 months of age, but those with
25(OH)D ,50 nmol/L were the lightest. As for length,
we observed a slow linear growth until the age of
6 months and an accelerated growth from 6 to 12months
of age in those with higher UCB 25(OH)D. Furthermore,
infants with higher vitamin D status at 12 months had
lower weight and length-adjusted weight at 12 months
Table 3. Associations Between 25(OH)D Concentrations and Infant Growth at 6 mo Follow-up





nmol/L, n = 671
Model 1, unadjusted 20.02 (20.06 to 0.01) 20.03 (20.07 to 0.01) 20.03 (20.07 to 0.01) 20.02 (20.05 to 0.02)
P value for linear
association
0.22 0.15 0.17 0.36
P value for quadratic
association
0.92 0.15 0.02 0.08
Model 2, adjustedb 20.02 (20.05 to 0.01) 20.03 (20.07 to 0.00) 20.03 (20.07 to 0.01) 20.02 (20.05 to 0.01)
P value for linear
association
0.12 0.08 0.13 0.22
P value for quadratic
association
0.45 0.32 0.02 0.12
UCB 25(OH)D, 10 nmol/L,
n = 780
Model 1, unadjusted 20.04 (20.06 to 20.01) 20.01 (20.04 to 0.02) 0.00 (20.03 to 0.03) 20.03 (20.06 to 20.01)
P value for linear
association
0.006 0.55 0.84 0.01
P value for quadratic
association
0.49 0.42 0.83 0.79
Model 2, adjustedb 20.03 (20.05 to 20.01) 0.00 (20.01 to 0.02) 0.01 (20.02 to 0.04) 20.02 (20.03 to 0.00)
P value for linear
association
0.008 0.87 0.51 0.20
P value for quadratic
association
0.28 0.19 0.57 0.52
Data are b coefficients (95% CI) per 10 nmol/L higher in 25(OH)D concentration based on linear regression.
aNumber of subjects vary in analyses due to missing values of head circumferences; for Pregnancy 25(OH)D in model 1, n = 650 and in model 2, n = 649;
for UCB 25(OH)D in model 1, n = 759 and in model 2, n = 757.
bModel 2 is adjusted for the corresponding birth size SDS, maternal and paternal height z scores, and Infant 25(OH)D, which served as a marker of infant
supplemental vitamin D intake [except for Infant 25(OH)D].
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of age, with the lightest and thinnest infants having
25(OH)D .125 nmol/L. These results give insight into
how vitamin D status affects postnatal growth in healthy
infants in a mostly vitamin D–sufficient population.
Evidence has been inconsistent concerning associa-
tions between maternal vitamin D status and postnatal
growth. The few studies in populations with relatively
low 25(OH)D have found positive (22, 23), negative
(23), or lacking (24) associations between maternal
25(OH)D and infant length or weight among 1- to
6-month-old infants. In Gambian mothers with relatively
high mean pregnancy 25(OH)D (103 to 111 nmol/L),
vitamin D status was unrelated to infant growth at
3 months of age (25). However, we found that higher
Pregnancy and UCB 25(OH)D predicted slower infant
growth until 6 months of age. In the Bangladeshi study
with 134 infants, of which 26% were stunted during the
follow-up, maternal supplementation of 875 mg/wk
resulted in divergent mean UCB 25(OH)D between
supplemented and placebo-treated mothers (103 vs
39 nmol/L) (9). Opposed to our findings, this study found
that maternal supplementation increased infant length at
1 and 2months but no longer at 4 and 6months and then
again at 12 months of age (9). In older infants (9 to







Pregnancy 25(OH)D, 10 nmol/L,
n = 671










P value for linear association 0.62 0.20 0.16 0.39 0.04
P value for quadratic
association
0.11 0.29 0.02 0.48 0.37










P value for linear association 0.44 0.13 0.15 0.30 0.04
P value for quadratic
association
0.02 0.52 0.01 0.65 0.37
UCB 25(OH)D, 10 nmol/L, n = 780










P value for linear association 0.59 0.28 0.27 0.045 0.26
P value for quadratic
association
0.97 0.91 0.82 0.49 0.79










P value for linear association 0.87 0.76 0.54 0.44 0.38
P value for quadratic
association
0.89 0.74 0.88 0.27 0.58
Infant 25(OH)D, 10 nmol/L,
n = 798










P value for linear association 0.04 0.009 0.049 0.03 0.15
P value for quadratic
association
0.33 0.04 0.06 0.42 0.35










P value for linear association 0.11 0.01 0.02 0.16 0.12
P value for quadratic
association
0.58 0.06 0.04 0.61 0.35
Data are b coefficients (95% CI) per 10 nmol/L higher in 25(OH)D concentration based on linear regression.
aNumber of subjects vary in analyses due to missing values of head circumferences; for Pregnancy 25(OH)D in model 1, n = 666 and in model 2, n = 665;
for UCB 25(OH)D in model 1, n = 775 and in model 2, n = 773; for Infant 25(OH)D in model 1, n = 793 and in model 2, n = 791.
bNumber of subjects vary in analyses due to missing values of MUAC; for Pregnancy 25(OH)D, n = 644; for UCB 25(OH)D, n = 742; and for Infant
25(OH)D, n = 760.
cModel 2 is adjusted for the corresponding birth size SDS (except for MUAC; the covariate was length-adjusted birth weight), maternal and paternal
height z scores, and Infant 25(OH)D, which served as a marker of infant supplemental vitamin D intake [except when Infant 25(OH)D was dependent].









elsinki. Social science library user on 23 April 2019
18 months), the relation of maternal vitamin D status
with infant growth has similarly been conflicting (5, 6, 8,
9, 22, 23, 25). In our study, the possibly disadvantageous
effect of high Pregnancy and UCB 25(OH)D on several
infant growth indicators remained to some extent until
12 months of age. Our finding is somewhat contrary to a
Dutch multiethnic study, in which slow fetal growth but
enhanced postnatal growth was observed in infants of
mothers with 25(OH)D ,30 nmol/L compared with
those with 25(OH)D .50 nmol/L (23). However, our
results may suggest a similar catch-up growth but, in
contrast, in infants of mothers with high 25(OH)D.
Together, these results may indicate an inverse U-shaped
association between maternal 25(OH)D and infant
growth, as has been proposed to exist between maternal
vitamin D status and fetal growth (26, 27).We previously
reported in this cohort an inverse relationship between
UCB 25(OH)D and newborn head circumference (17).
This finding was still apparent at 6 and 12 months but
attenuated when adjusting for birth head circumference
and parental height.
In addition to Pregnancy and UCB 25(OH)D, also
high Infant 25(OH)D was negatively associated with
postnatal growth; the strongest associations appeared
with weight and length-adjusted weight. These findings
are in line with a Danish study that found 25(OH)D
(mean 77 nmol/L) at 9 months to associate negatively
with length and BMI (28). However, two previous vi-
tamin D supplementation trials in infants found no effect
on growth between different dosages (12, 29). By con-
trast, in Indian low-birth-weight infants, the vitamin D
supplementation from the age of 1 week until 6 months
increased infant length and weight at 6 months but no
longer at 3 to 6 years (11). In that study, vitamin D
deficiency was highly prevalent in the placebo group
(73%) (11). The inconsistent findings on vitamin D and
infant postnatal growth may be due to ethnic, genetic,
geographical, nutritional status, and lifestyle differences
Figure 1. The effect of (a) Pregnancy (n = 671) and (b) UCB (n = 780) 25(OH)D on infant growth parameters at the age of 6 months. 25(OH)D
concentration is expressed in categories of ,50 nmol/L, 50–74.9 nmol/L (reference group), 75–125 nmol/L, and .125 nmol/L. Values are means
with 95% CIs adjusted for corresponding birth size SDS, maternal and paternal height z scores, and Infant 25(OH)D, which served as a marker
of infant supplemental vitamin D intake. P values are only shown if statistically significant (P , 0.05) between the reference group and other
groups. Number of subjects in Pregnancy 25(OH)D categories: ,50, n = 25; 50–74.9, n = 218; 75–125, n = 412; and .125, n = 16; and in
UCB 25(OH)D: ,50, n = 29; 50–74.9, n = 294; 75–125, n = 425; and .125, n = 32.
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among study populations (30–32) and, above all, dif-
ferences in 25(OH)D concentrations. However, this is
difficult to prove, as there is a lack of study populations
with both low and high 25(OH)D values. Furthermore,
previous studies have applied varying cutoff values for
25(OH)D (8, 31). Ong et al. (8) suggested that severe
vitamin D deficiency (,30 nmol/L) may impair child
growth, but beyond that, there might not be any
association between vitamin D status and early life
growth. However, studies involving populations with
especially high 25(OH)D are limited, and many studies
have presented only restricted group-level data.
Taken together, our results suggest that an inverse
U-shaped association may exist between 25(OH)D and
postnatal growth, as slower growth was more evident in
the group of 25(OH)D,50 nmol/L and.125 nmol/L in
Figure 2. The effect of (a) Pregnancy (n = 671), (b) UCB (n = 780), and (c) Infant (n = 798) 25(OH)D on infant growth parameters at the age of
12 months. 25(OH)D concentration is expressed in categories of ,50 nmol/L, 50–74.9 nmol/L (reference group), 75–125 nmol/L, and .125
nmol/L. Values are means with 95% CIs adjusted for corresponding birth size SDS (except for MUAC; the covariate was length-adjusted birth
weight), maternal and paternal height z scores, and Infant 25(OH)D, which served as a marker of infant supplemental vitamin D intake [except
when Infant 25(OH)D was independent]. P values are only shown if statistically significant (P , 0.05) between the reference group and other
groups. Number of subjects in Pregnancy 25(OH)D categories: ,50, n = 25; 50–74.9, n = 218; 75–125, n = 412; and .125, n = 16, in UCB
25(OH)D: ,50, n = 29; 50–74.9, n = 294; 75–125, n = 425; and .125, n = 32; and in Infant 25(OH)D: ,50, n = 10; 50–74.9, n = 160;
75–125, n = 493; and .125, n = 135.
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several growth parameters, although the limited number
of subjects in both extreme ends of the 25(OH)D range
constrained our analysis. The inverse U-shaped or J-shaped
relationship between vitamin D status and health is sup-
ported by observations in adults (33). In addition,
our previous finding of a positive association between
UCB 25(OH)D and inflammatory markers further sup-
port the possible adverse effect of high 25(OH)D on
infant health (34). The rather high Pregnancy and UCB
25(OH)D in our cohort can be explained by the fact that
almost all mothers (95%) in our study were taking vi-
tamin D supplements during pregnancy, with a mean
daily intake of 16 mg (16). In addition, vitamin D–
fortified foods are commonly used in Finland (13). In
addition to vitamin D, folic acid is also recommended
for pregnant women in Finland, from the planning of
pregnancy until gestational week 12; however, this
recommendation was not valid at the time of this study.
Iron supplementation is not routinely recommended.
With regard to infants, based on the VIDI study pro-
tocol, infants received vitamin D supplements of 10 mg
or 30 mg daily, leading to relatively high 25(OH)D.
Because our study only included infants born term with
normal birth weight, it remains unknown whether these
results can be extrapolated to children born preterm or
with low or high birth weight.
Infant growth is regulated by several factors, including
those related to mineral homeostasis, circulating endo-
crine factors, and local regulators of the growth plate
function. The nature of our study did not allow us to
explore potential mechanisms for adverse growth out-
comes caused by high 25(OH)D concentrations. High
vitamin D status may affect calcium and phosphate
homeostasis. However, we have previously shown that
whereas Infant 25(OH)D correlated positively with
ionized calcium concentration, no severe hypercalcemia
developed (35). Furthermore, our previous study showed
that urine calcium excretion was similar in 3-month-old
infants supplemented with 10, 30, or 40 mg vitamin D3
and that 25(OH)D did not correlate with bone param-
eters (29). In the current study, the mean PTH concen-
tration was lower in the higher 25(OH)D category,
suggesting that there may be mild changes that could
impact growth plate function (36) via the PTH-PTH–
related peptide axis or the calcium-sensing receptor (37).
We did not measure 1,25(OH)2 vitamin D [1,25(OH)2D]
concentrations, but it is possible that high 25(OH)D
leads to increased 1,25(OH)2D, which in turn may have a
negative effect on growth due to increased osteoclasto-
genesis (38). In genetically modified mice, high maternal
1,25(OH)2D levels adversely affected the total amount of
calcium stored in fetal bones (39). The GH–IGF-1 axis
plays an important role in the regulation of childhood
growth, and although some studies have shown a positive
effect of vitamin D supplementation on IGF-1 in children
(40), it is unknown whether supranormal 25(OH)D
concentrations have a similar positive effect.
A strength and limitation of this study is in the re-
cruitment, which took place in a single hospital; this en-
abled standardized data collection, but a multicenter study
might have resulted in a more diverse study population. A
limitation was the inability to use data on infant vitamin D
supplementation because of the ongoing double-blind
intervention. However, we applied the attained 25(OH)
D concentration as a reflection of the total vitamin D
intake. Furthermore, the limited number of subjects with
low 25(OH)D concentration may have restrained our
analyses. We used multiple outcome variables, as we
wanted to evaluate growth across the infantile period. The
multiple outcome variables increase the possibility that
some associations arise by chance. However, results are
parallel with each other. The strength of our study is the
varied and in-depth approach to analyze the relationships
among Pregnancy, UCB, and Infant 25(OH)D on infant
growth. In addition, we were able to adjust our analyses
for several potential confounders to identify the in-
dependent role of vitamin D in growth regulation.
Conclusion
In our large cohort, high 25(OH)D concentrations in
pregnancy, UCB, and infancy were associated with
slower growth in infants at 6 and 12 months of age.
Overall, our findings suggest an inverse U-shaped asso-
ciation between vitamin D status and infant postnatal
growth. Although the underlying mechanisms and direct
clinical implications remain to be further explored, our
results indicate that, in Finland, an adequate maternal
and infant vitamin D status has been achieved with a
daily vitamin D supplementation of 10 mg and with vi-
tamin D food fortification. We urge caution in aiming
for a higher maternal or infant 25(OH)D concentration
with excessive supplementation, as this might have un-
expected and possibly disadvantageous effects on infant
growth.
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Ward L, DiMeglio LA, Atapattu N, Cassinelli H, Braegger C,
Pettifor JM, Seth A, Idris HW, Bhatia V, Fu J, Goldberg G,
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Mäkitie OM, Andersson S. Maternal vitamin D status, gestational
diabetes and infant birth size. BMC Pregnancy Childbirth. 2017;
17(1):420.
18. HolickMF, BinkleyNC, Bischoff-Ferrari HA,GordonCM,Hanley
DA, Heaney RP, Murad MH, Weaver CM; Endocrine Society.
Evaluation, treatment, and prevention of vitamin D deficiency: An
endocrine society clinical practice guideline. J Clin Endocrinol
Metab. 2011;96(7):1911–1930.
19. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton
SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs
CS, Mayne ST, Rosen CJ, Shapses SA. The 2011 report on dietary
reference intakes for calcium and vitamin D from the Institute of
Medicine: what clinicians need to know. J Clin Endocrinol Metab.
2011;96(1):53–58.









elsinki. Social science library user on 23 April 2019
20. Saari A, Sankilampi U, HannilaML, Kiviniemi V, Kesseli K, Dunkel
L. New Finnish growth references for children and adolescents aged
0 to 20 years: Length/height-for-age, weight-for-length/height, and
body mass index-for-age. Ann Med. 2011;43(3):235–248.
21. De Stavola BL, Nitsch D, dos Santos Silva I, McCormack V, Hardy
R, Mann V, Cole TJ, Morton S, Leon DA. Statistical issues in life
course epidemiology. Am J Epidemiol. 2006;163(1):84–96.
22. Eckhardt CL, Gernand AD, Roth DE, Bodnar LM. Maternal vi-
tamin D status and infant anthropometry in a US multi-centre
cohort study. Ann Hum Biol. 2015;42(3):215–222.
23. Leffelaar ER, Vrijkotte TG, van Eijsden M. Maternal early preg-
nancy vitamin D status in relation to fetal and neonatal growth:
results of the multi-ethnic Amsterdam Born Children and their
Development cohort. Br J Nutr. 2010;104(1):108–117.
24. Sauder KA, Koeppen HJ, Shapiro ALB, Kalata KE, Stamatoiu AV,
RinghamBM,GlueckDH,Norris JM, DabeleaD. Prenatal vitamin
D intake, cord blood 25-hydroxyvitamin D, and offspring body
composition: The healthy start study. Nutrients. 2017;9(7):E790.
25. Prentice A, Jarjou LM, Goldberg GR, Bennett J, Cole TJ,
Schoenmakers I. Maternal plasma 25-hydroxyvitamin D concen-
tration and birthweight, growth and bone mineral accretion of
Gambian infants. Acta Paediatr. 2009;98(8):1360–1362.
26. Bodnar LM, Catov JM, Zmuda JM, Cooper ME, Parrott MS,
Roberts JM, Marazita ML, Simhan HN. Maternal serum 25-
hydroxyvitamin D concentrations are associated with small-for-
gestational age births in white women. J Nutr. 2010;140(5):
999–1006.
27. Zhu P, Tong SL, Hu WB, Hao JH, Tao RX, Huang K, Mou Z,
Zhou QF, Jiang XM, Tao FB. Cord blood 25-hydroxyvitamin D
and fetal growth in the China-Anhui birth cohort study. Sci Rep.
2015;5:14930.
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